Marrow Cellution™ vs. Traditional BMA Harvest Project

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-25

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Six patients with diagnosed bone loss of the hip who have consented to minimally invasive repair will be approached to participate in the study. Participants will have the liquid portion of bone marrow collected using the Zimmer Biomet Biocue system, which is the standard system used by physicians at The Ohio State University, and the novel Marrow Cellutions system™. Bone marrow liquid will be collected from the surgical hip using the Zimmer Biomet Biocue system, and the Marrow Cellutions system™ will be used to collect bone marrow liquid from the non-surgical hip. Following collection, the bone marrow liquid will be processed using the respective systems to concentrate the cells and molecules found in the bone marrow liquid. As part of the standard of care for this arthroscopic procedure, concentrated bone marrow liquid processed using the Zimmer Biomet Biocue system will be delivered to the surgical site as an adjunct to promote healing. Concentrated bone marrow liquid prepared with the Zimmer Biomet Biocue system is given as part of the standard of care for patients undergoing minimally invasive treatment for bone loss of the hip; therefore, the target population for this study are individuals between the ages of 18-50 years with confirmed bone loss of the hip who have consented to minimally invasive repair. In addition to the concentrated bone marrow liquid prepared using the Zimmer Biomet Biocue system, patients will also have bone marrow liquid collected from the non-surgical hip using the Marrow Cellutions™ system. Only concentrated bone marrow liquid produced with the Zimmer Biomet Biocue system will be given to the patient. All concentrated bone marrow liquid produced with the Marrow Cellutions™ system will be sent to the laboratory for analysis. Additionally, white blood cells will be concentrated into an autologous protein solution (APS) using the Zimmer Biomet Plasmax system from blood collected using a routine blood draw. All protein solution produced will be sent to the laboratory for analysis. No protein solution will be given to the patient. As the bone marrow liquid collection using the Marrow Cellutions™ system and the blood draw to produce protein solution using the Zimmer Biomet Plasmax system are being performed for research,

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Collection of Bone Marrow From Healthy Volunteers and Patients for the Production of Clinical Bone Marrow Stromal Cell (BMSC) Products

NCT01071577

Bone Marrow Stromal Cells

TERMINATED

A Study of Carbon 13-based Deep Labelling of Bone Marrow Cells

NCT07057583

Monoclonal Gammopathy of Undetermined Significance (MGUS) Non-IgM Monoclonal Gammopathy of Undetermined Significance

ENROLLING_BY_INVITATION

Clinical Outcomes of Autologous Bone Marrow Aspirate Concentrate Injections for Musculoskeletal Conditions

NCT02981394

Musculoskeletal Pain Osteoarthritis Tendinopathy +1 more

WITHDRAWN

Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip

NCT02065167

Avascular Necrosis of the Femoral Head

COMPLETED PHASE2

Autologous Bone Marrow Aspirate Treatment for Early-Stage Osteonecrosis

NCT06123481

Osteonecrosis of the Femoral Head Avascular Necrosis of the Femoral Head

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

l

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hip Arthropathy Avascular Necrosis of Bone Subchondral Cysts

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bilateral Hip Bone Marrow Collection

Collection of bone marrow aspirate from both hips. One collected using the Zimmer Biomet Biocue system and the other using the Marrow Cellution system.

Group Type EXPERIMENTAL

Bone Marrow Collection

Intervention Type DEVICE

Comparing the two collection systems for bone marrow aspirate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bone Marrow Collection

Comparing the two collection systems for bone marrow aspirate

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients aged 18 - 50
* patients undergoing hip arthroscopy for subchondral bone cysts and/or avascular necrosis

Exclusion Criteria

* patients with a history of hematologic issues including anemia and sickle cell anemia
* patients with a history of leukemia, lymphoma, or other bone marrow related diseases
* patients with diabetes
* patients with a history of bone marrow aspirate

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No